keyword
Keywords Antibody-dependent cellular to...

Antibody-dependent cellular toxicity

https://read.qxmd.com/read/37548440/igg-antibodies-mediated-gold-nanoparticles-conjugated-to-methotrexate-as-targeted-chemotherapy-for-lung-cancer
#21
JOURNAL ARTICLE
Asad Syed, Abu Baker, Mohamed Mohany, Abdallah M Elgorban, Mohd Sajid Khan, Salim S Al-Rejaie
Vincamine, a natural chemical, was used as a reducing agent in the synthesis of IgG antibodies mediated biogenic gold nanoparticles (IgGAuNPs). Eventually, the synthesised IgGAuNPs were bioconjugated with the chemotherapeutic drug methotrexate (MTX-IgGAuNPs). The IgG isotype can target cancer cells through polymorphic Fc gamma receptors (FcγRs) and have therapeutic effects. They can restrict cell division by inhibiting different intracellular signal transduction pathways and activating NK cells and macrophages through antibody-dependent cellular cytotoxicity and macrophage-mediated antibody-dependent phagocytosis, respectively...
December 2023: Artificial Cells, Nanomedicine, and Biotechnology
https://read.qxmd.com/read/37327664/chlorin-e6-ce6-loaded-plaque-specific-liposome-with-enhanced-photodynamic-therapy-effect-for-atherosclerosis-treatment
#22
JOURNAL ARTICLE
Lin Zou, Yao Zhang, Nihad Cheraga, Oluwatosin David Abodunrin, Kai-Yun Qu, Li Qiao, Yu-Qing Ma, Li-Juan Chen, Ning-Ping Huang
Recently, photodynamic therapy (PDT) has been considered as a new strategy for atherosclerosis treatment. Targeted delivery of photosensitizer could significantly reduce its toxicity and enhance its phototherapeutic efficiency. CD68 is an antibody that can be conjugated to nano-drug delivery systems to actively target plaque sites, owing to its specific binding to CD68 receptors that are highly expressed on the surfaces of macrophage-derived foam cells. Liposomes are very popular nanocarriers due to their ability to encapsulate a wide range of therapeutic compounds including drugs, microRNAs and photosensitizers, and their ability to be surface-modified with targeting moieties leading to the development of nanocarriers with an improved targeted ability...
June 9, 2023: Talanta
https://read.qxmd.com/read/37259060/an-fc-muted-bispecific-antibody-targeting-pd-l1-and-4-1bb-induces-antitumor-immune-activity-in-colorectal-cancer-without-systemic-toxicity
#23
JOURNAL ARTICLE
Lian-Sheng Cheng, Min Zhu, Yan Gao, Wen-Ting Liu, Wu Yin, Pengfei Zhou, Zhongliang Zhu, Liwen Niu, Xiaoli Zeng, Dayan Zhang, Qing Fang, Fengrong Wang, Qun Zhao, Yan Zhang, Guodong Shen
BACKGROUND: Resistance to immune checkpoint inhibitor (ICI) therapy narrows the efficacy of cancer immunotherapy. Although 4-1BB is a promising drug target as a costimulatory molecule of immune cells, no 4-1BB agonist has been given clinical approval because of severe liver toxicity or limited efficacy. Therefore, a safe and efficient immunostimulatory molecule is urgently needed for cancer immunotherapy. METHODS: HK010 was generated by antibody engineering, and the Fab/antigen complex structure was analyzed using crystallography...
May 31, 2023: Cellular & Molecular Biology Letters
https://read.qxmd.com/read/37208128/bispecific-antibodies-redirect-synthetic-agonistic-receptor-modified-t-cells-against-melanoma
#24
JOURNAL ARTICLE
Florian Märkl, Mohamed-Reda Benmebarek, Julius Keyl, Bruno L Cadilha, Martina Geiger, Clara Karches, Hannah Obeck, Melanie Schwerdtfeger, Stefanos Michaelides, Daria Briukhovetska, Sophia Stock, Jakob Jobst, Philipp Jie Müller, Lina Majed, Matthias Seifert, Anna-Kristina Klüver, Theo Lorenzini, Ruth Grünmeier, Moritz Thomas, Adrian Gottschlich, Richard Klaus, Carsten Marr, Michael von Bergwelt-Baildon, Simon Rothenfusser, Mitchell P Levesque, Markus Vincent Heppt, Stefan Endres, Christian Klein, Sebastian Kobold
BACKGROUND: Melanoma is an immune sensitive disease, as demonstrated by the activity of immune check point blockade (ICB), but many patients will either not respond or relapse. More recently, tumor infiltrating lymphocyte (TIL) therapy has shown promising efficacy in melanoma treatment after ICB failure, indicating the potential of cellular therapies. However, TIL treatment comes with manufacturing limitations, product heterogeneity, as well as toxicity problems, due to the transfer of a large number of phenotypically diverse T cells...
May 2023: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/37104309/characterization-of-monoamine-oxidase-a-in-tropical-liver-fluke-fasciola-gigantica
#25
JOURNAL ARTICLE
Mirza Ahmar Beg, Abdur Rehman, Lubna Rehman, Rizwan Ullah, Faiza Farhat, Sobia Wasim, S M A Abidi
Fasciola gigantica, responsible for the zoonotic disease fasciolosis, pose a great threat to the livestock and human health worldwide. The triclabendazole (TCBZ) has been used for decades as a broad spectrum anthelmintic to control this perilous disease but the emergence of resistance in flukes against TCBZ has prompted researchers across the world to explore for new drugs and antigenic targets. World Health Organization has strongly recommended the utilization of neurobiologically significant biomolecules as new drug/antigenic targets because of their significant role in the physiology of parasites...
2023: PloS One
https://read.qxmd.com/read/37048069/derivation-and-preclinical-characterization-of-cyt-303-a-novel-nkp46-nk-cell-engager-targeting-gpc3
#26
JOURNAL ARTICLE
Antonio Arulanandam, Liang Lin, Hao-Ming Chang, Martine Cerutti, Sylvie Choblet, Peng Gao, Armin Rath, Armand Bensussan, Jean Kadouche, Daniel Teper, Ofer Mandelboim, Wei Li
Glypican-3 (GPC3) is an oncofetal antigen that is highly expressed in multiple solid tumors, including hepatocellular carcinoma, and is barely expressed in adult normal tissues except the placenta. NKp46 activation receptor is expressed in all-natural killer (NK) cells, including tumor-infiltrating NK cells. FLEX-NKTM is a platform for the production of tetravalent multifunctional antibody NK cell engagers (NKE). CYT-303 was designed using the FLEX-NK scaffold, incorporating a novel humanized NKp46 binder that does not induce NKp46 internalization and a humanized GPC3 binder that targets the membrane-proximal lobe to mediate NK cell-redirected killing of HCC tumors...
March 24, 2023: Cells
https://read.qxmd.com/read/36991390/first-in-human-phase-1-clinical-trial-of-anti-core-1-o-glycans-targeting-monoclonal-antibody-neo-201-in-treatment-refractory-solid-tumors
#27
JOURNAL ARTICLE
Christopher B Cole, Maria Pia Morelli, Massimo Fantini, Markku Miettinen, Patricia Fetsch, Cody Peer, William D Figg, Tyler Yin, Nicole Houston, Ann McCoy, Stanley Lipkowitz, Alexandra Zimmer, Jung-Min Lee, Miroslava Pavelova, Erin N Villanueva, Kathryn Trewhitt, B Brooke Solarz, Maria Fergusson, Sharon A Mavroukakis, Anjum Zaki, Kwong Y Tsang, Philip M Arlen, Christina M Annunziata
BACKGROUND: NEO201 is a humanized IgG1 monoclonal antibody (mAb) generated against tumor-associated antigens from patients with colorectal cancer. NEO-201 binds to core 1 or extended core 1 O-glycans expressed by its target cells. Here, we present outcomes from a phase I trial of NEO-201 in patients with advanced solid tumors that have not responded to standard treatments. METHODS: This was a single site, open label 3 + 3 dose escalation clinical trial...
March 29, 2023: Journal of Experimental & Clinical Cancer Research: CR
https://read.qxmd.com/read/36965009/gene-modification-therapies-for-hereditary-diseases-in-the-fetus
#28
REVIEW
Citra N Z Mattar, Jerry K Y Chan, Mahesh Choolani
Proof-of-principle disease models have demonstrated the feasibility of an intrauterine gene modification therapy (in utero gene therapy (IUGT)) approach to hereditary diseases as diverse as coagulation disorders, haemoglobinopathies, neurogenetic disorders, congenital metabolic, and pulmonary diseases. Gene addition, which requires the delivery of an integrating or episomal transgene to the target cell nucleus to be transcribed, and gene editing, where the mutation is corrected within the gene of origin, have both been used successfully to increase normal protein production in a bid to reverse or arrest pathology in utero...
March 25, 2023: Prenatal Diagnosis
https://read.qxmd.com/read/36941881/targeted-treatment-of-relapsed-or-refractory-follicular-lymphoma-focus-on-the-therapeutic-potential-of-mosunetuzumab
#29
REVIEW
Paolo Lopedote, Mazyar Shadman
Follicular lymphoma is the most common indolent non-Hodgkin's lymphoma, and because of the incurable nature of this disorder, new therapies are constantly needed. The recently approved T-cell-dependent bispecific antibody mosunetuzumab showed promising results and manageable toxicities for patients with relapsed or refractory follicular lymphoma. Namely, as opposed to cellular immunotherapy options, this agent has the potential of being effective in patients with unfavorable features with a tolerable rate and severity of cytokine release syndrome, immune effector cell-associated neurotoxicity, and infectious complications...
2023: Cancer Management and Research
https://read.qxmd.com/read/36872527/cadonilimab-a-tetravalent-pd-1-ctla-4-bispecific-antibody-with-trans-binding-and-enhanced-target-binding-avidity
#30
JOURNAL ARTICLE
Xinghua Pang, Zhaoliang Huang, Tingting Zhong, Peng Zhang, Zhongmin Maxwell Wang, Michelle Xia, Baiyong Li
Clinical studies have shown that combination therapy of antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death-1 (PD-1) significantly improves clinical benefit over PD-1 antibody alone. However, broad application of this combination has been limited by toxicities. Cadonilimab (AK104) is a symmetric tetravalent bispecific antibody with a crystallizable fragment (Fc)-null design. In addition to demonstrating biological activity similar to that of the combination of CTLA-4 and PD-1 antibodies, cadonilimab possess higher binding avidity in a high-density PD-1 and CTLA-4 setting than in a low-density PD-1 setting, while a mono-specific anti-PD-1 antibody does not demonstrate this differential activity...
2023: MAbs
https://read.qxmd.com/read/36851141/proteome-wide-screening-of-potential-vaccine-targets-against-brucella-melitensis
#31
JOURNAL ARTICLE
Mahnoor Malik, Saifullah Khan, Asad Ullah, Muhammad Hassan, Mahboob Ul Haq, Sajjad Ahmad, Alhanouf I Al-Harbi, Samira Sanami, Syed Ainul Abideen, Muhammad Irfan, Muhammad Khurram
The ongoing antibiotic-resistance crisis is becoming a global problem affecting public health. Urgent efforts are required to design novel therapeutics against pathogenic bacterial species. Brucella melitensis is an etiological agent of brucellosis, which mostly affects sheep and goats but several cases have also been reported in cattle, water buffalo, yaks and dogs. Infected animals also represent the major source of infection for humans. Development of safer and effective vaccines for brucellosis remains a priority to support disease control and eradication in animals and to prevent infection to humans...
January 25, 2023: Vaccines
https://read.qxmd.com/read/36765861/chemotherapeutics-used-for-high-risk-neuroblastoma-therapy-improve-the-efficacy-of-anti-gd2-antibody-dinutuximab-beta-in-preclinical-spheroid-models
#32
JOURNAL ARTICLE
Sascha Troschke-Meurer, Maxi Zumpe, Lena Meißner, Nikolai Siebert, Piotr Grabarczyk, Hannes Forkel, Claudia Maletzki, Sander Bekeschus, Holger N Lode
Anti-disialoganglioside GD2 antibody ch14.18/CHO (dinutuximab beta, DB) improved the outcome of patients with high-risk neuroblastoma (HR-NB) in the maintenance phase. We investigated chemotherapeutic compounds used in newly diagnosed patients in combination with DB. Vincristine, etoposide, carboplatin, cisplatin, and cyclophosphamide, as well as DB, were used at concentrations achieved in pediatric clinical trials. The effects on stress ligand and checkpoint expression by neuroblastoma cells and on activation receptors of NK cells were determined by using flow cytometry...
January 31, 2023: Cancers
https://read.qxmd.com/read/36695691/tigit-agonism-alleviates-costimulation-blockade-resistant-rejection-in-a-regulatory-t-cell-dependent-manner
#33
JOURNAL ARTICLE
Christina R Hartigan, Katherine P Tong, Danya Liu, Sonia J Laurie, Mandy L Ford
Belatacept-based immunosuppression in kidney transplantation confers fewer off-target toxicities than calcineurin inhibitors but comes at a cost of increased incidence and severity of acute rejection, potentially due to its deleterious effect on both the number and function of Foxp3+ regulatory T cells (Tregs). TIGIT is a CD28 family coinhibitory receptor expressed on several subsets of immune cells including Tregs. We hypothesized that coinhibition through TIGIT signaling could function to ameliorate costimulation blockade-resistant rejection...
February 2023: American Journal of Transplantation
https://read.qxmd.com/read/36689726/acalabrutinib-and-high-frequency-low-dose-subcutaneous-rituximab-for-initial-therapy-of-chronic-lymphocytic-leukemia
#34
JOURNAL ARTICLE
Danielle S Wallace, Clive S Zent, Andrea M Baran, Patrick M Reagan, Carla Casulo, Geoffrey Rice, Jonathan W Friedberg, Paul M Barr
BTK inhibitors are an effective therapy for previously untreated patients with CLL but require indefinite duration treatment that can result in cumulative toxicities. Novel combinations of agents that provide deep remissions could allow for fixed duration therapy. Acalabrutinib, unlike ibrutinib, does not inhibit anti-CD20 monoclonal antibody dependent cellular phagocytosis, making it a suitable partner drug to rituximab. Using standard dosing (375mg/m2) of rituximab causes loss of target membrane CD20 immune cells and exhaustion of the finite cytotoxic capacity of the innate immune system...
January 23, 2023: Blood Advances
https://read.qxmd.com/read/36672190/high-dose-ascorbate-in-combination-with-anti-pd1-checkpoint-inhibition-as-treatment-option-for-malignant-melanoma
#35
JOURNAL ARTICLE
Markus Burkard, Heike Niessner, Christian Leischner, Alban Piotrowsky, Olga Renner, Luigi Marongiu, Ulrich M Lauer, Christian Busch, Tobias Sinnberg, Sascha Venturelli
Ascorbate acts as a prooxidant when administered parenterally at high supraphysiological doses, which results in the generation of hydrogen peroxide in dependence on oxygen. Most cancer cells are susceptible to the emerging reactive oxygen species (ROS). Accordingly, we evaluated high-dose ascorbate for the treatment of the B16F10 melanoma model. To investigate the effects of ascorbate on the B16F10 cell line in vitro, viability, cellular impedance, and ROS production were analyzed. In vivo, C57BL/6NCrl mice were subcutaneously injected into the right flank with B16F10 cells and tumor-bearing mice were treated intraperitoneally with ascorbate (3 g/kg bodyweight), immunotherapy (anti-programmed cell death protein 1 (PD1) antibody J43; 2 mg/kg bodyweight), or both treatments combined...
January 7, 2023: Cells
https://read.qxmd.com/read/36627666/in-silico-design-and-evaluation-of-an-epitope-based-serotype-independent-promising-vaccine-candidate-for-highly-cross-reactive-regions-of-pneumococcal-surface-protein-a
#36
JOURNAL ARTICLE
Elnaz Afshari, Reza Ahangari Cohan, Fattah Sotoodehnejadnematalahi, Seyed Fazlollah Mousavi
BACKGROUND: The pathogenicity of pneumococcus with high morbidity, mortality, and multi-drug resistance patterns has been increasing. The limited coverage of the licensed polysaccharide-based vaccines and the replacement of the non-vaccine serotypes are the main reasons for producing a successful serotype-independent vaccine. Pneumococcal surface protein A (PspA) is an extremely important virulence factor and an interesting candidate for conserved protein-based pneumococcal vaccine classified into two prominent families containing five clades...
January 10, 2023: Journal of Translational Medicine
https://read.qxmd.com/read/36614128/active-targeting-of-versatile-nanocomplex-using-the-novel-biomarker-of-breast-cancer-stem-cells
#37
JOURNAL ARTICLE
Eun-Young Koh, Keun-Sik Kim, Hee-Bin Park, Jong-Seok Kim, Pyung-Hwan Kim
Breast cancer in women is one of the most common life-threatening malignancies. Despite of the development for the improved treatment, there are still many limitations to overcome. Among them, cancer stem cells (CSCs) are well known for tumor formation, development, cellular heterogeneity, and cancer recurrence. Therefore, to completely cure breast cancer, treatment of both cancer and CSC is required. To selectively target CSCs, we generated a liposome-based smart nano complex using CEACAM 6 (CD66c) antibody (Ab), a novel cell-surface biomarker of breast-derived CSCs (BCSCs) discovered in our previous research...
December 30, 2022: International Journal of Molecular Sciences
https://read.qxmd.com/read/36610490/phase-i-study-safety-and-efficacy-of-ex-vivo-expanded-allogeneic-natural-killer-cells-mg4101-with-rituximab-for-relapsed-refractory-b-cell-non-hodgkin-lymphoma
#38
JOURNAL ARTICLE
Dok Hyun Yoon, Youngil Koh, Miyoung Jung, Jeong-Eun Kwak, Eui-Cheol Shin, Yu Kyeong Hwang, Won Seog Kim
BACKGROUND: The prognosis of non-Hodgkin lymphoma (NHL) remains poor, with an unmet need for novel therapies. MG4101, an ex vivo-expanded allogeneic natural killer cell, can enhance rituximab antibody-dependent cytotoxicity in relapsed/refractory B-cell non-Hodgkin lymphoma (r/rNHL). OBJECTIVES: To assess the safety and efficacy of MG4101 plus rituximab for patients with r/rNHL. STUDY DESIGN: Patients received escalating doses of intravenous MG4101 plus rituximab every 2 weeks...
January 4, 2023: Transplantation and cellular therapy
https://read.qxmd.com/read/36569901/potent-immunomodulatory-and-antitumor-effect-of-anti-cd20-il2no-alpha-tri-functional-immunocytokine-for-cancer-therapy
#39
JOURNAL ARTICLE
Ana Victoria Casadesús, Beatriz María Cruz, Wilden Díaz, Miguel Ángel González, Tania Gómez, Briandy Fernández, Addys González, Nuris Ledón, Katya Sosa, Kathleen Castro, Armando López, Claudia Plasencia, Yaima Ramírez, Jean-Luc Teillaud, Calixto Hernández, Kalet León, Tays Hernández
INTRODUCTION: The anti-CD20 antibody rituximab (RTX) has substantially improved outcomes of patients with B-cell lymphomas, although more efficient therapies are needed for refractory or relapsing lymphomas. An approach to increase the clinical effectiveness of anti-tumor therapy is the use of antibody-cytokine fusion proteins (immunocytokines (ICKs)) to deliver at the tumor site the antibody effector functions and cytokines that trigger anti-tumor activities. In particular, IL-2-based ICKs have shown significant results in preclinical studies but not in clinical trials due to the toxicity profile associated to high doses IL-2 and the undesired expansion of Tregs...
2022: Frontiers in Immunology
https://read.qxmd.com/read/36511698/characterization-of-a-novel-cd4-mimetic-compound-yir-821-against-hiv-1-clinical-isolates
#40
JOURNAL ARTICLE
Kaho Matsumoto, Takeo Kuwata, William D Tolbert, Jonathan Richard, Shilei Ding, Jérémie Prévost, Shokichi Takahama, George P Judicate, Takamasa Ueno, Hirotomo Nakata, Takuya Kobayakawa, Kohei Tsuji, Hirokazu Tamamura, Amos B Smith, Marzena Pazgier, Andrés Finzi, Shuzo Matsushita
Small CD4-mimetic compound (CD4mc), which inhibits the interaction between gp120 with CD4, acts as an entry inhibitor and induces structural changes in the HIV-1 envelope glycoprotein trimer (Env) through its insertion within the Phe43 cavity of gp120. We recently developed YIR-821, a novel CD4mc, that has potent antiviral activity and lower toxicity than the prototype NBD-556. To assess the possibility of clinical application of YIR-821, we tested its antiviral activity using a panel of HIV-1 pseudoviruses from different subtypes...
December 13, 2022: Journal of Virology
keyword
keyword
72918
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.